Inherited Thrombophilia^[*]: Part 1

• 

Based upon the World Health Organisation report of a Joint World Health Organisation/International Society on Thrombosis and Haemostasis Meeting held in Geneva, 6-8 November 1995. Published with permission of the World Health Organisation. Meeting Rapporteur; 2ISTH Secretariat, 6WHO Secretariat

• References

• 1 Egeberg O. Inherited antithrombin III deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-530
• 2 Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc. Natl Acad Sci USA 1993; 90: 1004-1008
• 3 Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ron-de H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
• 4 Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-1508
• 5 Voorberg J, Roelse J, Koopman R, Biiller H, Berends F, ten Cate JW, Mertens K, van Mourik JA. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994; 343: 1535-1536
• 6 Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Bou-lyjenkov V, Chandy M, Dahlback B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: Part 2. Thromb Haemost 1996 76. (publication, Dec. 1996)
• 7 Lane DA, Caso R. Antithrombin: structure, genomic organisation, function and inherited deficiency. Bailliere’s Clin Haem 1989; 2: 961-998
• 8 Blajchman M, Austin R, Femandez-Rachubinski F, Sheffield W. Molecular basis of inherited antithrombin deficiency. Blood 1992; 80: 2159-2171
• 9 Olds RJ, Lane DA, Mille B, Chowdhury V, Thein SL. Antithrombin: the principal inhibitor of thrombin. Semin Thromb Haemostas 1994; 20: 353-372
• 10 Bock SC, Wion KL, Vehar GA, Lawn RM. Cloning and expression of the cDNA for human antithrombin III. Nucl Acids Res 1982; 10: 8113-8125
• 11 Chandra T, Stackhouse R, Kidd VJ, Woo SLC. Isolation and sequence characterisation of a cDNA clone of human antithrombin III. Proc Natl Acad Sci USA 1983; 80: 1845-1848
• 12 Prochownik EV, Markam AF, Orkin SH. Isolation of a cDNA clone for human antithrombin III. J Biol Chem 1983; 258: 8389-8394
• 13 Bock SC, Harris JF, Balazs I, Trent JM. Assignment of the human antithrombin III structural gene to chromosome Cytogenet. Cell Genet 1985; 39: 67-69
• 14 Bock SC, Marrinan JA, Radziejewska E. Antithrombin III Utah: proline-407 to leucine mutation in a highly conserved region near the inhibitor reactive site. Biochemistry 1988; 27: 6171-6178
• 15 Olds RJ, Lane DA, Chowdhury V, De Stefano V, Leone G, Thein SL. Complete nucleotide sequence of the antithrombin gene: evidence for homologous recombination causing thrombophilia. Biochemisty 1993; 32: 4216-4224
• 16 Olds RJ, Lane DA, Chowdhury V, Sas G, Pabinger I, Auberger K, Thein SL. (ATT) trinucleotide repeats in the antithrombin gene and their use in determining the origin of repeated mutations. Hum Mutat 1994; 4: 31-41
• 17 Lane DA, Olds RJ, Conrad J, Boisclair M, Bock SC, Hultin M, Abildgaard U, Ireland H, Thompson E, Sas G, Horrelou MH, Tamponi G, Thein SL. Pleiotropic effects of antithrombin strand 1C substitution mutations. J Clin Invest 1992; 90: 2422-2433
• 18 Lane DA, Olds RJ, Boisclair M, Chowdhury V, Thein SL, Cooper DN, Blajchman M, Perry D, Emmerich J, Aiach M. Antithrombin III mutation database: first update. Thromb Haemost 1993; 70: 361-369
• 19 Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost 1987; 58: 1094
• 20 Lane DA, Ireland H, Olds RJ, Thein SL, Perry DJ, Aiach M. Antithrombin III: a database of mutations. Thromb Haemost 1991; 66: 657-661
• 21 Borg JY, Owen MC, Soria C, Soria J, Caen J, Carrell RW. Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser. J Clin Invest 1988; 81: 1292-1296
• 22 Mille B, Watton J, Barrowcliffe TW, Mani JC, Lane DA. Role of N and C terminal amino acids in antithrombin binding to pentasaccharide. J Biol Chem 1994; 269: 29435-29443
• 23 Millar DS, Lopez A, White D, Abraham G, Laursen B, Holding S, Reverter JC, Reynand J, Martinowitz U, Hayes JPLA, Kakkar VV, Cooper DN. Screening for mutations in the antithrombin III (AT3) gene causing recurrent venous thrombosis by single strand conformation polymorphism analysis. Human Mutation 1993; 2: 324-326
• 24 van Boven HH, Olds RJ, Thein SL, Reitsma PH, Lane DA, Briet E, Vandenbroucke JP, Rosendaal FR. Hereditary antithrombin deficiency: heterogeneity of the molecular basis and mortality in Dutch families. Blood 1994; 84: 4209-4213
• 25 Jochmans K, Lissens W, Vervoot R, Peeters S, De Wale M, Liebaers I. Antithrombin-Gly 424 Arg: a novel point mutation responsible for type I antithrombin deficiency and neonatal thrombosis. Blood 1994; 83: 146-151
• 26 Jochmans K, Lissens W, Yin T, Michiels JJ, van der Luit L, Peerlinck K, Vervoot R, De Wale M, Liebaers I. Molecular basis for type I antithrombin deficiency: identification of two novel mutations and evidence for a de novo splice mutation. Blood 1994; 84: 3742-3748
• 27 Millar DS, Wacey AI, Ribando J, Melissari E, Laursen B, Woods P, Kakkar VV, Cooper DN. Three novel missense mutations in the antithrombin III (AT3) gene causing recurrent venous thrombosis. Human Genetics 1995; 94: 509-512
• 28 Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb 1992; 12: 135-145
• 29 Esmon CT. Molecular events that control the protein C anticoagulant pathway. Thromb Haemost 1993; 70: 29-35
• 30 Dahlback B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 1995; 77: 1-43
• 31 Foster D, Davie EW. Characterization of a cDNA coding for human protein C. Proc Natl Acad Sci USA 1984; 81: 4766-4770
• 32 Beckmann RJ, Schmidt RJ, Santerre RF, Plutzky J, Crabtree GR, Long GL. The structure and evolution of a 461 amino acid human protein C precursor and its messenger RNA, based upon the DNA sequence of cloned human liver cDNAs. Nucleic Acids Res 1985; 13: 5233-5247
• 33 Foster DC, Yoshitake S, Davie EW. The nucleotide sequence of the gene for human protein C. Proc Natl Acad Sci USA 1985; 82: 4673-4677
• 34 Plutzky J, Hoskins JA, Long GL, Crabtree GR. Evolution and organization of the human protein C gene. Proc Natl Acad Sci USA 1986; 83: 546-550
• 35 Patracchini P, Aiello V, Palazzi P, Calzolari E, Bemardi F. Sublocalization of the human protein C gene on chromosome 2ql3-ql4. Hum Genet 1989; 81: 191-192
• 36 Reitsma PH, Poort SR, Bernardi F, Gandrille S, Long GL, Sala N, Cooper DN. Protein C deficiency: a database of mutations. For the Protein C & S Subcommittee of the Scientific and Standardization Committee of the In-temational Society on Thrombosis and Haemostasis. Thromb Haemost 1993; 69: 77-84
• 37 Reitsma PH, Bemadi F, Doig RG, Gandrille S, Greengard JS, Ireland H, Krawczak M, Lind B, Long GL, Poort SR, Saito H, Sala N, Witt I, Cooper D. Protein C deficiency: A database of mutations, 1995 update. Thromb Haemost 1995; 73: 876-889
• 38 te Lintel Hekkert W, Bertina RM, Reitsma PH. Two RFLPS approximately 7 kb 5’ of the human protein C gene. Nucleic Acids Res 1988; 16: 11849
• 39 Aiach M, Gandrille S, Emmerich J. A review of mutations causing deficiencies of antithrombin, protein C and protein S. Thromb Haemost 1995; 74: 81-89
• 40 Wacey AI, Pemberton S, Cooper DN, Kakkar VV, Tuddenham EG. A molecular model of the serine protease domain of activated protein C: application to the study of missense mutations causing protein C deficiency. Br J Haematol 1993; 84: 290-300
• 41 Greengard JS, Fisherg CL, Villoutreix B, Griffin JH. Structural basis for type I and type II deficiencies of antithrombotic plasma protein C: patterns revealed by three-dimensional molecular modelling of mutations of the protease domain. Proteins 1994; 18: 367-380
• 42 Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993; 268: 2872-2877
• 43 Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G, Griffin JH. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci USA 1994; 91: 2728-2732
• 44 Koppelman SJ, Hackeng TM, Sixma JJ, Bouma BM. Inhibition of the intrinsic factor X activating complex by protein S: Evidence for specific binding of protein S to Factor VIII. Blood 1995; 86: 1062-1071
• 45 Godowski PJ, Mark MR, Chen J, Sadick MD, Raab H, Hammonds RG. Reevaluation of the roles of protein S and Gas 6 as ligands for the receptor tyrosine kinase Rse/Tyro 3. Cell 1995; 82: 355-358
• 46 Benzakour O, Formstone C, Rahman S, Kanthou C, Dennehy U, Scully MF, Kakkar VV, Cooper DN. Evidence for a protein S receptor(s) on human vascular smooth muscle cells. Analysis of the binding characteristics and mitogenic properties of protein S on human vascular smooth muscle cells. Biochem J 1995; 308: 481-485
• 47 Dahlback B, Stenflo J. A natural anticoagulant pathway: protein C, S, C4b-binding protein and thrombomodulin. In: Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds). Churchill Livingstone, Edinburg 1994: 671-698
• 48 Lundwall A, Dackowski W, Cohen E, Shaffer M, Mahr A, Dahlback B, Stenflo J, Wydro R. Isolation and sequence of the cDNA for human protein S, a regular of blood coagulation. Proc Natl Acad Sci USA 1986; 83: 6716-6720
• 49 Hoskins JA, Norman DK, Beckmann RJ, Long GL. Cloning and characterisation of a human liver cDNA encoding a protein S precursor. Proc Natl Acad Sci USA 1987; 84: 349-353
• 50 Ploos van Amstel HK, van der Zanden AL, Reitsma PH, Bertina RM. Human protein S cDNA encodes Phe-16 and Tyr 222 in consensus sequences for the post-translational processing. FEBS Lett 1987; 222: 186-190
• 51 Edenbrandt CM, Lundwall A, Wydro R, Stenflo J. Molecular analysis of the gene for vitamin K dependent protein S and its pseudogene. Cloning and partial gene organization. Biochemistry 1990; 29: 7861-7868
• 52 Ploos van AmstelHK, Reitsma PH, van der Logt CP, Bertina RM. Intron-exon organization of the active human protein S gene PS alpha and its pseudogene PS beta: duplication and silencing during primate evolution. Biochemisty 1990; 29: 7853-7861
• 53 Schmidel DK, Tatro AV, Phelps LG, Tomczak JA, Long GL. Organization of the human protein S genes. Biochemistry 1990; 29: 7845-7852
• 54 Watkins PC, Eddy R, Fukushima Y, Byers MG, Cohen EH, Dackowski WR, Wydro RM, Shows TB. The gene for protein S maps near the centromere of human chromosome 3. Blood 1988; 71: 238-241
• 55 Ploos van Amstel HK, Reitsma PH, Hamulyak J, de Die Smulders CE, Mannucci PM, Bertina RM. A mutation in the protein S pseudogene is linked to protein S deficiency in a thrombophilic family. Thromb Haemost 1989; 62: 897-901
• 56 Diepstraten CM, Ploos van Amstel JK, Reitsma PH, Bertina RM. A CCA/CCG neutral dimorphism in the codon for Pro 626 of the human protein S gene PS alpha (PROS1). Nucleic Acids Res 1991; 19: 5091
• 57 Formstone CJ, Voke J, Tuddenham EGD, Jenkins E, Clark J, Layton M, Nicolaides K, Kakkar VV, Cooper DC. Prenatal exclusion of severe protein S deficiency by indirect RFLP analysis. Thromb Haemostas 1993; 69: 931
• 58 Marchetti G, Legnani C, Patracchini P, Gemmati D, Ferrati M, Palareti G, Coccheri S, Bernardi F. Study of a protein S gene polymorphism at DNA and mRNA level in a family with symptomatic protein S deficiency. Br J Haematol 1993; 85: 173-175
• 59 Comp PC. Laboratory evaluation of protein S status. Semin Thromb Hemost 1990; 16: 177-181
• 60 Zoller B, Garcia de Frutos P, Dahlback B. Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood 1995; 85: 3524-3531
• 61 Duchemin J, Gandrille S, Borgel D, Feurgard P, Alhenc-Gelas M, Mathe-ron C, Dreyfus M, Dupuy E, Juhan-Vague I, Aiach M. The Ser 460 Pro substitution of the protein S a (PROS1) gene is a frequent mutation associated with free protein S (type Ha) deficiency. Blood 1995; 86: 3436-3443
• 62 Bertina RM, Ploos van Amstel HK, van Wijngaarden A, Coenen J, Leem-huis MP, Deutz Terlouw PP, van der Linden IK, Reitsma PH. Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460. Blood 1990; 76: 538-548
• 63 Borgel D, Duchemin J, Matheron C, Aiach M, Gandrille S. Molecular defects responsible for type I and Ha protein S (PS) deficiencies in a panel of 120 French families. Thromb Haemostas 1995; 73: 1256
• 64 Reitsma PH, Ploos van Amstel HK, Bertina RM. Three novel mutations in five unrelated subjects with hereditary protein S deficiency type I. J Clin Invest 1994; 93: 486-492
• 65 Gomez E, Poort SR, Bertina RM, Reitsma PH. Identification of eight point mutations in protein S deficiency type I - Analysis of 15 pedigrees. Thromb Hemost 1995; 73: 750-755
• 66 Ploos van Amstel HK, Huisman MV, Reitsma PH, ten Cate JW, Bertina RM. Partial protein S gene deletion in a family with hereditary thrombophilia. Blood 1989; 73: 479-483
• 67 Schmidel DK, Nelson RM, Broxson Jr EH, Comp PC, Marlar RA, Long GL. A 5.3-kb deletion including exon XIII of the protein S alpha gene occurs in two protein S-deficient families. Blood 1991; 77: 551-559
• 68 Gandrille S, Borgel D, Eschwege GuffletV, Aillaud M, Dreyfus M, Matheron C, Gaussem P, Abgrall JF, Jude B, Sie P, Toulon P, Aiach M. Identification of 15 different candidate causal point mutations and three polymorphisms in 19 patients with protein S deficiency using a scanning method for the analysis of the protein S active gene. Blood 1995; 85: 130-138
• 69 Hayashi T, Nishioka J, Shigekiyo T, Daito S, Suzuki K. Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. Blood 1994; 83: 683-690
• 70 Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-31880
• 71 Nicolaes GAF, Tans G, Thomassen MCLGD, Hemker HC, Pabinger I, Varadi K, Schwarz HP, Rosing J. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor Va R506Q by activated protein C. J Biol Chem 1995; 270: 21158-21166
• 72 Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor Villa. J Biol Chem 1994; 269: 18735-18738
• 73 Jenny RJ, Tracy PB, Mann KG. The physiology and biochemistry of factor V. In: Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds). Churchill Livingstone, Edinburgh 1994: 465-476
• 74 Kane WH, Davie EW. Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin. Proc Natl Acad Sci USA 1986; 83: 6800-6804
• 75 Kane WH, Ichinose A, Hagen FS, Davie EW. Cloning of cDNAs coding for the heavy chain region and connecting regions of human factor V, a blood coagulation factor with four types of internal repeats. Biochemistry 1987; 26: 6508-6514
• 76 Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann KG. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA 1987; 84: 4846-4850
• 77 Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry 1992; 31: 3777-3785
• 78 Wang H, Riddell DC, Guinto ER, MacGillivray RT, Hamerton JL. Localization of the gene encoding human factor V to chromosome lq. Genomics 1988; 2: 324-328
• 79 Bayston T, Ireland H, Olds RJ, Thein SL, Lane DA. A polymorphism in the human coagulation factor V gene. Hum Mol Genet 1994; 3: 2085
• 80 Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-1538
• 81 Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1361-1362
• 82 Griffin JH, Heeb MJ, Kojima Y, Fernandez JA, Hackeng TM, Greengard JS. Activated protein C resistance: molecular mechanisms. Thromb Haemost 1995; 74: 444-488
• 83 Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995; 270: 4053-4057
• 84 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-1134
• 85 Ohlin A-K, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45 year old man presenting with thromboembolic disease. Blood 1995; 85: 330-336
• 86 Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995; 73: 151-161
• 87 Ohlin A-K, Marlar RA. Mutations in the thrombomodulin gene associated with thromboembolic disease. Thromb Haemost 1995; 73: 1096
• 88 Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocysteinemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14: 1080-1083
• 89 den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijer-mans PW, Bos GMJ. Is hyperhomocysteinaemia a risk factor for recurrent thrombosis. Lancet 1995; 345: 882-885
• 90 den Heijer M, Koster T, Blom HJ, Bos GMJ, Briet E, Reitsma PH, Van-denbrouke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Engl J Med 1996; 334: 759-762
• 91 Mudd SH, Levy HL, Skovby F. Disorders of transulfuration. In: The metabolic basis of inherited disease. Scriver CR, Beaudet AL, Sly WS, Valle D (eds). McGraw Hill, New York 1989: 693
• 92 Malinov MR. Homocysteine and arterial occlusive diseases. J Int Med 1994; 236: 603
• 93 Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Mathews RG, Boers GHJ. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrafolate reductase. Nature Genetics 1995; 10: 111-113
• 94 Dolan G, Preston FE. Familial plasminogen1 deficiency and thromboembolism. Fibrinolysis 1988; 2: 26-34
• 95 Santori MT, Patrassi GM, Theodoridis P, Perin A, Pielrogrande F, Girola-mi A. Heterozygous type I plasminogen deficiency is associated with an increased risk for thrombosis; a statistic analysis in 20 kindreds. Blood Coag Fibrinolysis 1994; 5: 889-893
• 96 Gladson CL, Scharrer I, Hach V, Beck KH, Griffin JH. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988; 59: 18-22
• 97 Tait RC, Walker ID, Islam SIA, Mitchell R, Davidson JF. Plasminogen levels and putative prevalence of deficiency in 4500 blood donors. Br J Haematol 1991; 77: 10
• 98 Ichinose A, Espling ES, Takamatsu J, Saito H, Shinmyozu K, Maruyama I, Petersen TE, Davie EW. Two types of abnormal plasminogen genes in families with a predisposition for thrombosis. Proc Natl Acad Sci USA 1991; 88: 115-119
• 99 Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine rich glycoprotein. J Biol Chem 1980; 255: 10214-10222
• 100 Engesser L, Kluft C, Briet E, Brommer EJ. Familial elevation of plasma histidine rich glycoprotein in a family with thrombophilia. Br J Haematol 1987; 67: 355-358
• 101 Castaman G, Ruggeri M, Burei F, Rodeghiero F. High levels of histidine rich glycoprotein and thrombotic diathesis. Report of two unrelated families. Thromb Res 1993; 69: 279-305
• 102 Souto JC, Gari M, Mateo J, Falkon L, Borrell M, Fontcuberta J. Congenital histidine rich glycoprotein deficiency and familial thrombophilia: a new case. Thromb Haemost 1995; 73: 952
• 103 Shigekiyo T, Kanazuka M, Azuma H, Oshima T, Kasaka K, Saito H. Congenital deficiency of histidine rich glycoprotein: failure to identify abnormalities in routine laboratory assays of hemostatic function, immunologic function and trace elements. J Lab Clin Med 1995; 125: 719-723
• 104 Bertina RM, van der Linden IK, Engesser L, Muller HP, Brommer EJP. Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemostas 1987; 57: 196-200
• 105 Bancsi LF, van der Linden IK, Bertina RM. Beta 2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 1992; 67: 649-653
• 106 Simioni P, Lazarro AR, Corer E, Salmistraro G, Girolami A. Constitutional heparin cofactor II deficiency and thrombosis: report of six patients belonging to two separate kindreds. Blood Coag Fibrinolysis 1990; 1: 351-356
• 107 Sie P, Dupouy D, Pichon J, Boneu B. Constitutional heparin cofactor II deficiency associated with recurrent thrombosis. Lancet 1985; 2: 414-416
• 108 Blinder MA, Andersson TR, Abildgaard U, Tollefsen DM. Heparin cofactor II Oslo: mutation of Arg 180 to His decreases the affinity for dermatan sulphate. J Biol Chem 1989; 264: 5128-5133
• 109 Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fischer M. The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from venous and/or arterial thromboembolism. Thromb Haemost 1992; 68: 285-290
• 110 Koster T, Rosendaal FR, Briet E, Vandenbroucke JP. John Hagemann’s factor and deep vein thrombosis: Leiden Thrombophilia Study. Br J Haematol 1994; 87: 422-424
• 111 Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet 1995; 345: 152-155
• 112 Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-1993
• 113 Heijboer H, Brandjes DP, Buller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-1516
• 114 Tait RC, Walker ID, Perry DJ, Carrell RW, Islam SIA, McCall F, Mitchell R, Davidson JF. Prevalence of antithrombin III deficiency subtypes in 4000 healthy blood donors. Thromb Haemost 1991; 65: 839
• 115 Tait RC, Walker ID, Islam SI, McCall F, Conkie JA, Wight M, Mitchell R, Davidson JF. Protein C activity in healthy volunteers-influence of age, sex, smoking and oral contraceptives. Thromb Haemost 1993; 70: 218-215
• 116 Tait RC, Walker ID, Islam SI, McCall F, Conkie JA, Mitchell R, Davidson JF. Influence of demographic factors on antithrombin III activity in a healthy population. Brit J Haematol 1993; 84: 476-480
• 117 Tait RC, Walker ID, Reitsma PH, Islam SI, McCall F, Poort SR, Conkie JA, Bertina RM. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995; 73: 87-93
• 118 Miletich J, Sherman L, Broze Jr G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-996
• 119 Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522
• 120 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction. N Engl J Med 1995; 332: 912-917
• 121 Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-1506
• 122 Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981; 10: 369-390
• 123 Hirsh J, Piovella F, Pini M. Congenital antithrombin III deficiency. Incidence and clinical features. Am J Med 1989; 87 (Suppl. 03) suppl 34S-38S
• 124 Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 1990; 63: 319-320
• 125 Koster T, Rosendaal FR, Briet E, van der Meer FJ, Colly LP, Trienekens PH, Poort SR, Reitsma PH, Vandenbroucke JP. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85: 2756-2761
• 126 Rosendaal FR, Heijboer H. Mortality related to thrombosis in congenital antithrombin III deficiency. Lancet 1991; 337: 1545
• 127 De Stefano V, Leone G. Mortality related to thrombosis in congenital antithrombin III deficiency. Lancet 1991; 337: 847-848
• 128 Cosgriff TM, Bishop DP, Hershgold EJ, Skolnick MH, Martin BA, Baty BJ, Carlson KJ. Familial antithrombin III deficiency: its natural history, genetics, diagnosis and treatment. Medicine 1983; 62: 209-220
• 129 Rosendaal FR, Heijboer H, Briet E, Buller H, Brandjes DPM, DeBruin K, Hommes DW, Vandenbroucke JP. Mortality in hereditary antihrombin III deficiency. Lancet 1991; 337: 260-262
• 130 Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373
• 131 Bovill EG, Bauer KA, Dickerman JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989; 73: 712-717
• 132 Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briet E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993; 341: 134-138
• 133 Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. Blood 1984; 64: 1297-1300
• 134 Broekmans AW, Bertina RM, Reinalda PootJ, Engesser L, Muller HP, Leeuw JA, Michiels JJ, Brommer EJ, Briet E. Hereditary protein S deficiency and venous thrombo-embolism. A study in three Dutch families. Thromb Haemost 1985; 53: 273-277
• 135 Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. Thromb Haemost 1993; 70: 1067-1071
• 136 Greengard JS, Eichinger S, Griffin JH, Bauer KA. Variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg → Gin mutation in the gene for factor V. N Engl J Med 1994; 331: 1559-1562
• 137 Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-1035
• 138 Zoller B, Berntsdotter A, Garcia de Frutos P, Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-3523
• 139 van Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdhury V, Bauer KA, Scharrer I, Conard J, Lane DA. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75: 417-421
• 140 Ireland H, Bayston TA, Chowdhury V, Thein SL, Conard J, Pabinger I, Lane DA. Factor V Leiden as an independent risk factor for thrombosis and antithrombin deficiency type II: heparin binding site. Thromb Haemost 1995; 73: 1361 (Abstr. 1764)
• 141 Pabinger I, Schneider B. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb Haemost 1994; 71: 548-552
• 142 Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457
• 143 Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutations of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-1596
• 144 Gomez E, Ledford MR, Pegelow CH, Reitsma PH, Bertina RM. Homozygous protein S deficiency due to a one base pair deletion that leads to a stop codon in exon III of the protein S gene. Thromb Haemost 1994; 71: 723-726
• 145 Borgel D, Gandrille S, Gouault Heilmann M, Aiach M. First frameshift mutation in the active protein S gene associated with a quantitative hereditary deficiency. Blood Coagul Fibrinolysis 1994; 5: 593-600
• 146 Formstone CJ, Wacey AI, Berg L, Rahman S, Bevan D, Rowley M, Voke J, Francesco B, Legnani F, Simioni P, Girolami A, Tuddenham EGD, Kakkary VV, Cooper DC. Detection and characterisation of seven novel protein S (PROS) gene lesions: Evaluation of reverse transcript-Polymerase Chain Reaction as a mutation screening strategy. Blood 1995; 86: 2632-2641
• 147 Briet E, Engesser L, Brommer EJP, Broekmans AW, Bertina RM. Thrombophilia: its causes and a rough estimate of its prevalence. Thromb Haemost 1987; 58: 39
• 148 Scharrer I, Hach-Wunderle V, Heyland H, Kuhn C. Incidence of defective tPA release in 158 unrelated young patients with venous thrombosis in comparison to PC-, PS-, ATIII-, fibrinogen-, and plasminogen deficiency. Thromb Haemost 1987; 58: 72
• 149 Ben Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost 1989; 61: 50-54
• 150 Tabernero MD, Tomas JF, Alberca I, Orfao A, Lopez Borrasca A, Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991; 36: 249-254